Cynata Therapeutics Limited (CYP.AX)
AUD 0.2
(11.43%)
AUD 0.2
(11.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -8.8 Million AUD | 46.76% |
| 2023 | -16.54 Million AUD | -139.74% |
| 2022 | -6.9 Million AUD | 24.01% |
| 2021 | -9.08 Million AUD | 13.62% |
| 2020 | -10.51 Million AUD | -4.49% |
| 2019 | -10.06 Million AUD | -64.1% |
| 2018 | -6.13 Million AUD | 3.18% |
| 2017 | -6.33 Million AUD | -2.44% |
| 2016 | -6.18 Million AUD | -55.49% |
| 2015 | -3.97 Million AUD | -27.32% |
| 2014 | -3.12 Million AUD | -268.13% |
| 2013 | -848.15 Thousand AUD | 51.31% |
| 2012 | -1.74 Million AUD | 35.34% |
| 2011 | -2.69 Million AUD | -26.39% |
| 2010 | -2.13 Million AUD | -54.93% |
| 2009 | -1.37 Million AUD | 35.56% |
| 2008 | -2.13 Million AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -7.08 Million AUD | 0.0% |
| 2024 FY | -12.54 Million AUD | 24.16% |
| 2024 Q4 | -13.08 Million AUD | 0.0% |
| 2023 Q2 | -6.97 Million AUD | 0.0% |
| 2023 Q4 | -9.31 Million AUD | 0.0% |
| 2023 FY | -16.54 Million AUD | -139.74% |
| 2022 Q2 | -1.16 Million AUD | 0.0% |
| 2022 Q4 | -5.17 Million AUD | 0.0% |
| 2022 FY | -6.9 Million AUD | 24.01% |
| 2021 Q2 | -4.95 Million AUD | 0.0% |
| 2021 FY | -9.08 Million AUD | 13.62% |
| 2021 Q4 | -4.42 Million AUD | 0.0% |
| 2020 Q2 | -7.07 Million AUD | 0.0% |
| 2020 FY | -10.51 Million AUD | -4.49% |
| 2020 Q4 | -3.71 Million AUD | 0.0% |
| 2019 Q2 | -3.1 Million AUD | 0.0% |
| 2019 FY | -10.06 Million AUD | -64.1% |
| 2019 Q4 | -5.62 Million AUD | 0.0% |
| 2018 Q4 | -2.94 Million AUD | 0.0% |
| 2018 FY | -6.13 Million AUD | 3.18% |
| 2018 Q2 | -1.81 Million AUD | 0.0% |
| 2017 Q4 | -3.56 Million AUD | 0.0% |
| 2017 Q2 | -1.02 Million AUD | 0.0% |
| 2017 FY | -6.33 Million AUD | -2.44% |
| 2016 Q2 | -2.46 Million AUD | 0.0% |
| 2016 Q4 | -2.61 Million AUD | 0.0% |
| 2016 FY | -6.18 Million AUD | -55.49% |
| 2015 FY | -3.97 Million AUD | -27.32% |
| 2015 Q4 | -2.55 Million AUD | 0.0% |
| 2015 Q2 | -1.41 Million AUD | 0.0% |
| 2014 FY | -3.12 Million AUD | -268.13% |
| 2014 Q4 | -1.37 Million AUD | 0.0% |
| 2014 Q2 | -1.75 Million AUD | 0.0% |
| 2013 Q3 | -212.03 Thousand AUD | 46.98% |
| 2013 Q2 | -399.95 Thousand AUD | 8.17% |
| 2013 Q1 | -435.51 Thousand AUD | 0.0% |
| 2013 FY | -848.15 Thousand AUD | 51.31% |
| 2013 Q4 | -448.2 Thousand AUD | -111.38% |
| 2012 Q4 | - AUD | 100.0% |
| 2012 Q2 | -435.51 Thousand AUD | 35.34% |
| 2012 Q1 | -673.56 Thousand AUD | 0.0% |
| 2012 FY | -1.74 Million AUD | 35.34% |
| 2012 Q3 | -435.51 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | 100.0% |
| 2011 Q3 | -673.56 Thousand AUD | 0.0% |
| 2011 Q2 | -673.56 Thousand AUD | -26.39% |
| 2011 Q1 | -532.9 Thousand AUD | 0.0% |
| 2011 FY | -2.69 Million AUD | -26.39% |
| 2010 Q3 | -532.9 Thousand AUD | 0.0% |
| 2010 Q2 | -532.9 Thousand AUD | -54.93% |
| 2010 Q4 | - AUD | 100.0% |
| 2010 Q1 | -343.97 Thousand AUD | 0.0% |
| 2010 FY | -2.13 Million AUD | -54.93% |
| 2009 Q2 | -343.97 Thousand AUD | 35.56% |
| 2009 FY | -1.37 Million AUD | 35.56% |
| 2009 Q3 | -343.97 Thousand AUD | 0.0% |
| 2009 Q1 | -533.77 Thousand AUD | 0.0% |
| 2009 Q4 | - AUD | 100.0% |
| 2008 Q4 | - AUD | 100.0% |
| 2008 Q2 | -533.77 Thousand AUD | 0.0% |
| 2008 FY | -2.13 Million AUD | 0.0% |
| 2008 Q3 | -533.77 Thousand AUD | 0.0% |
| 2008 Q1 | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2007 Q2 | - AUD | 0.0% |
| 2007 Q3 | - AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 190.649% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -503.643% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -48.326% |
| Biome Australia Limited | -1.91 Million AUD | -360.367% |
| Patrys Limited | -3.53 Million AUD | -148.871% |
| Orthocell Limited | -11.68 Million AUD | 24.597% |
| Imugene Limited | -140.93 Million AUD | 93.75% |
| Noxopharm Limited | -7.53 Million AUD | -16.893% |
| PYC Therapeutics Limited | -38.85 Million AUD | 77.333% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 28.447% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -22.563% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | -21.799% |
| CSL Limited | 5.64 Billion AUD | 100.156% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -22.451% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -187.609% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 117.921% |
| Starpharma Holdings Limited | -15.15 Million AUD | 41.896% |
| Nanollose Limited | -1.24 Million AUD | -604.733% |
| Memphasys Limited | -2.7 Million AUD | -225.737% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -312.815% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -328.284% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -99.05% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 40.082% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -206.492% |
| Race Oncology Limited | -13.38 Million AUD | 34.174% |
| Nyrada Inc. | -4.56 Million AUD | -93.142% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 64.852% |
| PharmAust Limited | -6.65 Million AUD | -32.278% |
| Immutep Limited | -44.93 Million AUD | 80.399% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 80.34% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 55.066% |
| BTC Health Limited | 1.05 Million AUD | 934.647% |
| Acrux Limited | -9.83 Million AUD | 10.434% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 103.898% |
| Biotron Limited | -5.15 Million AUD | -70.989% |
| Tissue Repair Ltd | -4.87 Million AUD | -80.64% |
| AdAlta Limited | -5.26 Million AUD | -67.4% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 81.343% |
| Hexima Limited | -1 Million AUD | -773.152% |
| AnteoTech Limited | -11.72 Million AUD | 24.889% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 86.473% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 60.057% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -91.928% |
| Actinogen Medical Limited | -12.83 Million AUD | 31.397% |
| Immuron Limited | -5.8 Million AUD | -51.831% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -55.31% |